- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05968495
Measuring Renuvion Soft Tissue Contraction Using Ultrasound
This is a prospective, single-center, non-randomized study of up to 5 subjects who are receiving treatment with the Renuvion APR system following power-assisted liposuction in the abdomen per investigator standard of care. Ultrasound images of soft tissue contraction will be taken on abdomen prior to and during the procedure. Measurements of contraction will be calculated from the ultrasound images by an ultrasonographer. All adverse events and expected treatment effects will be documented.
Follow-up photographs and ultrasound images will be captured at D30, D45, D60, D90, D180, D270, & D365.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective, single-center, non-randomized study of up to 5 subjects who are receiving treatment with the Renuvion APR system following power-assisted liposuction in the abdomen per investigator standard of care. Subjects may also have other body areas treated at the same time. Demographic information, medical history, and procedure details will be documented. Pre- and post-procedure care are per investigator standard of care and documented. Video may be taken during the procedure.
Ultrasound images of soft tissue contraction will be taken on abdomen prior to and during the procedure. Measurements of contraction will be calculated from the ultrasound images by an ultrasonographer. At baseline, photographs will be taken of the treatment areas. Surface area measurements will be taken of each treatment area prior to study treatment.
Post-procedure care will be as per investigator standard of care and documented. All adverse events and expected treatment effects will be documented.
Follow-up photographs and ultrasound images will be captured at D30, D45, D60, D90, D180, D270, & D365.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Kari Larson
- Phone Number: 800-537-2790
- Email: kari.larson@apyxmedical.com
Study Contact Backup
- Name: Emily Hughes
- Phone Number: 800-537-2790
- Email: emily.hughes@apyxmedical.com
Study Locations
-
-
Washington
-
Olympia, Washington, United States, 98501
- Pearl Plastic Surgery
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients who are scheduled for a procedure involving the use of Renuvion for the contraction of subcutaneous soft tissue. Patients undergoing procedures involving Renuvion alone and/or Renuvion following liposuction will be included.
- Patients who have acceptable cardiopulmonary health for outpatient surgery.
- Willing and able to comply with protocol requirements, including obtaining study-required images/photos and assessments, and returning for follow-up visits.
- Willing to release rights for the use of study photos, including in potential publication.
- Able to communicate with the site via video and/or photographs, in the event of a virtual follow-up visit.
- Able to read, understand, sign and date the informed consent document (English only).
Exclusion Criteria:
- BMI of greater than 35.
- Diabetes mellitus with A1C score >7.
- Active cigarette smokers or nicotine vape users.
- History of connective tissue disease (Ehlers Danlos, Cutis Laxa, Pseudoxanthoma Elasticum, Marfan's, etc.)
- Patients who, in the opinion of the investigator, is not an appropriate candidate for the study.
- Patients requiring a concomitant procedure in the Renuvion treatment area that could impact the ultrasound measurements or the effectiveness results.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Renuvion APR System Treatment
Subjects are receiving treatment with the Renuvion APR system following power-assisted liposuction in the abdomen per investigator standard of care.
Subjects may also have other body areas treated at the same time.
|
The Renuvion® APR (Apyx Plasma/RF) handpiece is a sterile, single use electrosurgical (monopolar) device intended to be used in conjunction with a compatible generator for the delivery of radiofrequency energy and helium plasma for cutting, coagulation and ablation of soft tissue during open surgical procedures.
Radiofrequency energy is delivered to the handpiece by the generator and used to energize the electrode.
When helium gas is passed over the energized electrode, a helium plasma is generated for cutting, coagulation or ablation of soft tissue during open surgical procedures.
The compatible generators operate at an adjustable power of up to 40 W (expressed as 0 - 100% where 100% is 40 W) and provide an adjustable helium gas flow of 1 - 5 L/Min.
APR Handpiece has a non-extendable electrode to generate helium plasma.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Analysis of contraction
Time Frame: Day 365
|
Percentage of soft tissue contraction measured by an ultrasonographer on baseline ultrasound images compared to follow-up images.
|
Day 365
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
IPR Review
Time Frame: Day 365
|
Improvement in appearance of skin laxity in the treatment area assessed by selection of the correct post-treatment image as determined by a masked, qualitative assessment of photographs by blinded independent reviewers
|
Day 365
|
Physician Global Aesthetic Improvement
Time Frame: Day 365
|
The Principal Investigator, sub-investigator or qualified clinician delegated by the principal investigator, will complete a PGAIS assessing overall aesthetic improvement in the treatment area
|
Day 365
|
Subject Global Aesthetic Improvement
Time Frame: Day 365
|
The subject will complete a SGAIS assessing overall aesthetic improvement in the treatment area
|
Day 365
|
Patient Satisfaction
Time Frame: Day 365
|
The subject will complete a Patient Satisfaction Questionnaire (PSQ)
|
Day 365
|
Energy Delivered
Time Frame: Day 0
|
Analysis of energy delivered (J/cm2)
|
Day 0
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events
Time Frame: Day 365
|
Analysis of adverse events
|
Day 365
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Chris Nichols, Investigator
- Principal Investigator: Dan Albershardt, Investigator
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- APX-23-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Skin Laxity
-
Rocky Mountain Biosystems, Inc.CompletedLaxity of SkinUnited States
-
Rocky Mountain Biosystems, Inc.CompletedLaxity of SkinUnited States
-
Merz North America, Inc.Ulthera, IncCompletedMild to Moderate Skin Laxity Under the Chin | Mild to Moderate Skin Laxity on NeckUnited States
-
Apsara Medical CorporationCompleted
-
Ulthera, IncCompletedSkin Laxity of the décolletéUnited States
-
Ulthera, IncUniversity of Texas Southwestern Medical CenterCompletedMild to Moderate Skin Laxity on Cheek | Mild to Moderate Skin Laxity on Upper Neck | Mild to Moderate Subcutaneous Fat on Cheek | Mild to Moderate Subcutaneous Fat on Upper Neck
-
Derming SRLCompletedFace Skin LaxityItaly
-
Nashville Centre for Laser and Facial SurgeryBausch HealthUnknownFacial Skin Laxity
-
Ulthera, IncCompletedFacial Skin LaxityUnited States
-
Endo PharmaceuticalsCompletedLaxity; Skin | Cellulite | Edematous Fibrosclerotic PanniculopathyUnited States
Clinical Trials on Renuvion APR Handpiece
-
Apyx MedicalCompleted
-
Apyx MedicalRecruitingSkin Laxity | Tissue Breakdown | Collagen Degeneration | Collagen Shrinkage | Tissue DegenerationUnited States
-
Apyx MedicalActive, not recruiting
-
Apyx MedicalActive, not recruitingLabia Enlarged | Labium; HypertrophyUnited States
-
Apyx MedicalCompletedLax SkinUnited States
-
Apyx MedicalCompletedGynecomastiaUnited States
-
Candela CorporationWithdrawn
-
Apyx MedicalCompleted
-
Stony Brook UniversityUnknownRectal AdenocarcinomaUnited States
-
Cataract and Laser Institute of Southern OregonSengiCompletedCataractUnited States